|
1
|
Murray CJ and Lopez AD: Mortality by cause
for eight regions of the world: Global Burden of Disease Study.
Lancet. 349:1269–1276. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sakamoto M: Pathology of early
hepatocellular carcinoma. Hepatol Res. 37(Suppl 2): S135–S138.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tung-Ping Poon R, Fan ST and Wong J: Risk
factors, prevention, and management of postoperative recurrence
after resection of hepatocellular carcinoma. Ann Surg. 232:10–24.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
von Lindern M, Fornerod M, van Baal S, et
al: The translocation (6;9), associated with a specific subtype of
acute myeloid leukemia, results in the fusion of two genes, dek and
can, and the expression of a chimeric, leukemia-specific dek-can
mRNA. Mol Cell Biol. 12:1687–1697. 1992.PubMed/NCBI
|
|
5
|
Carro MS, Spiga FM, Quarto M, et al: DEK
expression is controlled by E2F and deregulated in diverse tumor
types. Cell Cycle. 5:1202–1207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lü ZL, Luo DZ and Wen JM: Expression and
significance of tumor-related genes in HCC. World J Gastroenterol.
11:3850–3854. 2005.PubMed/NCBI
|
|
7
|
Kappes F, Khodadoust MS, Yu L, et al: DEK
expression in melanocytic lesions. Hum Pathol. 42:932–938. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khodadoust MS, Verhaegen M, Kappes F, et
al: Melanoma proliferation and chemoresistance controlled by the
DEK oncogene. Cancer Res. 69:6405–6413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng J, Kohler ME, Chen Q, et al: Serum
from mice immunized in the context of Treg inhibition identifies
DEK as a neuroblastoma tumor antigen. BMC Immunol. 8:42007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Datta A, Adelson ME, Mogilevkin Y, et al:
Oncoprotein DEK as a tissue and urinary biomarker for bladder
cancer. BMC Cancer. 11:2342011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wise-Draper TM, Morreale RJ, Morris TA, et
al: DEK proto-oncogene expression interferes with the normal
epithelial differentiation program. Am J Pathol. 174:71–81. 2009.
View Article : Google Scholar :
|
|
12
|
Liu S, Wang X, Sun F, et al: DEK
overexpression is correlated with the clinical features of breast
cancer. Pathol Int. 62:176–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Abba MC, Sun H, Hawkins KA, et al: Breast
cancer molecular signatures as determined by SAGE: correlation with
lymph node status. Mol Cancer Res. 5:881–890. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Privette Vinnedge LM, McClaine R, Wagh PK,
et al: The human DEK oncogene stimulates β-catenin signaling,
invasion and mammosphere formation in breast cancer. Oncogene.
30:2741–2752. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kondoh N, Wakatsuki T, Ryo A, et al:
Identification and characterization of genes associated with human
hepatocellular carcinogenesis. Cancer Res. 59:4990–4996.
1999.PubMed/NCBI
|
|
16
|
Lin LJ and Chen LT: The role of DEK
protein in hepatocellular carcinoma for progression and prognosis.
Pak J Med Sci. 29:778–782. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edmondson H and Steiner P: Primary
carcinoma of the liver: a study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sitwala KV, Adams K and Markovitz DM: YY1
and NF-Y binding sites regulate the transcriptional activity of the
dek and dek-can promoter. Oncogene. 21:8862–8870. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu HG, Scholten I, Gruss C and Knippers R:
The distribution of the DEK protein in mammalian chromatin. Biochem
Biophys Res Commun. 358:1008–1014. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grasemann C, Gratias S, Stephan H, et al:
Gains and overexpression identify DEK and E2F3 as targets of
chromosome 6p gains in retinoblastoma. Oncogene. 24:6441–6449.
2005.PubMed/NCBI
|
|
21
|
Evans AJ, Gallie BL, Jewett MA, et al:
Defining a 0.5-mb region of genomic gain on chromosome 6p22 in
bladder cancer by quantitative-multiplex polymerase chain reaction.
Am J Pathol. 164:285–293. 2004. View Article : Google Scholar
|
|
22
|
Castellano G, Torrisi E, Ligresti G, et
al: The involvement of the transcription factor Yin Yang 1 in
cancer development and progression. Cell Cycle. 8:1367–1372. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wise-Draper TM, Mintz-Cole RA, Morris TA,
et al: Overexpression of the cellular DEK protein promotes
epithelial transformation in vitro and in vivo. Cancer Res.
69:1792–1799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wise-Draper TM, Allen HV, Jones EE, et al:
Apoptosis inhibition by the human DEK oncoprotein involves
interference with p53 functions. Mol Cell Biol. 26:7506–7519. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wise-Draper TM, Allen HV, Thobe MN, et al:
The human DEK proto-oncogene is a senescence inhibitor and an
upregulated target of high-risk human papillomavirus E7. J Virol.
79:14309–14317. 2005. View Article : Google Scholar : PubMed/NCBI
|
